Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel announced new GAVRETO (pralsetinib) data to be presented at ESMO Congress 2026 in Madrid, including a rapid oral session on pooled ARROW and TAPISTRY analysis in RET fusion-positive solid tumors. The pooled analysis of 49 patients showed a 53% overall response rate with 12.2 months median duration of response, including an 88% ORR in previously-treated pancreatic tumors. Thyroid cancer patients showed an 81.3% ORR, and first-line NSCLC patients on pralsetinib had a 75% ORR versus 26% on prior standard of care.
Key figures
- Drug Name
- GAVRETO (pralsetinib)
- Phase Of Trial
- Pooled analysis of ARROW and TAPISTRY trials
- Orr thyroid
- 81.3%
- Orr pancreatic
- 88% (7/8)
- Orr pooled solid tumors
- 53%
- Patients pooled analysis
- 49
- Orr first line nsclc vs soc
- 75% vs 26%
- Median duration of response months
- 12.2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.